The status of glucose intolerance in breast cancer patients without DM history after systemic treatment with surgery and/or chemo-therapy
10.3969/j.issn.1000-8179.20131408
- VernacularTitle:无糖尿病病史的乳腺癌患者系统治疗后糖耐量异常状况研究
- Author:
Linjie LU
;
Ruiyu WANG
;
Lingquan KONG
;
Guangyan JI
;
Shengchun LIU
;
Hongyuan LI
;
Kainan WU
- Publication Type:Journal Article
- Keywords:
breast cancer;
glucose intolerance;
undiagnosed diabetes;
prediabetes;
oncodiabetology
- From:
Chinese Journal of Clinical Oncology
2014;46(4):250-253
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To determine the status of glucose intolerance in breast cancer patients without DM history after combined treatment with surgery and/or chemotherapy through an oral glucose tolerance test (OGTT). Methods:All 121 breast cancer patients more than 3 months after combined treatments with surgery and/or chemotherapy and without the diagnosis of diabetes underwent OGTT and fasting. Then, 2 h glucose levels were measured to identify glucose tolerance and diabetes. Meanwhile, six patients with a history of diagnosed diabetes did not undergo OGTT. Results:The median ages of all breast cancer patients and the mean duration after combined treatments with surgery and/or chemotherapy were 50.4 years and 19 months, respectively. Among the 121 breast cancer pa-tients without the history of diabetes, the incidences of diabetes, prediabetes, and normal glucose intolerance were 19.8%(24 cases), 45.5%(55 cases) and 34.7%(42 cases), respectively. Among all breast cancer patients, the incidences of previously diagnosed diabetes, undiagnosed diabetes, and prediabetes were 4.72%, 18.9%, and 43.3%, respectively. The ratio of previously undiagnosed diabetes was about 80%. About 80.0% of undiagnosed diabetes and 74.5% of prediabetes met the criteria for elevated 2 h plasma glucose levels through OGTT instead of elevated fasting glucose levels. Conclusion: Breast cancer patients during follow-up after combined treat-ments with surgery and/or chemotherapy highly suffer from glucose intolerance, with high incidences of undiagnosed diabetes and pre-diabetes. OGTT should be made for breast cancer patients after combined treatments for early diagnosis, prevention, and treatment of di-abetes.
